IBRX (ImmunityBio, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IBRX (ImmunityBio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

IBRX

ImmunityBio, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

ImmunityBio (IBRX): Assessing Valuation After Q3 Revenue Surge and Narrowed Losses
Nov 13, 2025
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Nov 13, 2025
ImmunityBio: Q3 Earnings Snapshot
Nov 5, 2025
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Nov 5, 2025
ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion
Oct 1, 2025
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients
Sep 20, 2025
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8
Sep 15, 2025
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
Sep 8, 2025
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study
Sep 6, 2025
ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma
Aug 31, 2025
ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform
Aug 28, 2025
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
Aug 26, 2025
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
Aug 19, 2025
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
Aug 17, 2025

Reviews